Citations

Showing 10 of 108081 citations.

Extra-Immunization as a Clinical Indicator for Fragmentation of Care
Darden, Paul M. , Gustafson, Kristina K., Nietert, Paul J. , Jacobson, Robert M.

Mayo Clinic

Public Health Reports® | January 25, 2017 | Volume: 126 | Issue: 2_suppl | Pages: 48-59

10.1177/00333549111260s207 | PMID 21812169 Get It

Objectives. We assessed whether extra-immunization can serve as a clinical indicator for fragmentation of care. Methods. Using public-use files of the 1999–2003 National Immunization Survey, we classified children 19–35 months of age by their vaccination providers for the degree of fragmentation of care as ordered from lowest with one vaccine provider, to increasing fragmentation with multiple providers in one facility type, to multiple providers in more than one facility type. Extra-immunization was defined conservatively based on the year-specific recommendations of the Advisory Committee on Immunization Practices (ACIP) for immunizations due before 18 months of age. Of note, 1999–2003 transitioned from oral to inactivated poliovirus vaccines. Results. The rate for extra-immunization was 9.4% (95% confidence interval [CI] 9.2, 9.7). Of single vaccines, the rate for polio vaccine was highest (5.7%, 95% CI 5.5, 6.0). Extra-immunization was lowest for the 69% of children with only one vaccination provider (6.4%, 95% CI 6.1, 6.7), was higher in children who had more than one vaccination provider with one vaccination facility type (13.9%, 95% CI 13.2, 14.6), and highest with more than one facility type (24.1%, 95% CI 22.5, 25.6). Logistic regression (including race/ethnicity, language, provider type, survey year, and a parent-held immunization record) confirmed that multiple providers (adjusted odds ratio [AOR] = 2.30), multiple facility types (AOR=4.67), Spanish language (AOR=1.29), and race/ethnicity (black AOR=1.16, Hispanic AOR=1.31) were each associated with extra-immunization. Excluding poliovirus vaccine from the analysis, AORs for multiple providers and multiple facility types increased to 3.64 and 8.95, respectively. Conclusions. Extra-immunization is associated with receiving immunizations from multiple providers and multiple facility types.
The Effect of Systemic Triamcinolone Acetonide on Nerve Repair
Bansberg, Stephen F. , McCaffrey, Thomas V.

Mayo Clinic

Otolaryngology–Head and Neck Surgery | January 25, 2017 | Volume: 96 | Issue: 2 | Pages: 158-164

10.1177/019459988709600208 | PMID 3120090 Get It

The effects of timed‐release pellets of triamcinolone acetonide on sciatic nerve regeneration were studied. Bilateral nerve defects were created in 18 rats. One defect was sutured primarily, while the contralateral side was grafted with a 1 cm autogenous graft. Nerve regeneration was assessed at 20 weeks by muscle‐twitch strength and compound action potential parameters measured proximal and distal to the repair site. Conduction velocity and regenerative index (ratio of distal to proximal compound action potential area) were calculated. Significant improvement of the regenerative index and twitch strength occurred in animals treated with a 0.5 mg 21‐day‐release pellet. Improvement occurred in animals treated with 0.5 mg 60‐day pellets, but the difference was not significant. The findings suggest that regeneration was enhanced as a result of increased numbers of axons that made distal connections in the animals that received 21‐day‐release triamcinolone systemically. Corticosteroid therapy may benefit motor nerve repair.
Immunosuppressive Therapy in Heart Transplantation
Li, April Yingfang, Nwankwo, Ifeyinwa S., Huang, Zhi , Lu, Yun , Yao, Yali, Li, Yan , Zhang, Bin

Mayo Clinic

Advances in Medical Diagnosis, Treatment, and Care | January 25, 2017 | Volume: No volume available | Issue: No issue available | Pages: 212-231

10.4018/978-1-5225-2092-4.ch012 Get It

Heart transplantation is a surgical procedure performed on patients with end-stage heart failure or other irreversible heart disease, Heart transplant prolongs the life of severe heart disease patients. Most of the receipts could survive more than 2-3 years, five-year survival rate could reach 70-80% with immunosuppressive therapy, rejection still an important problem after transplantation. Currently, traditional calcineurin inhibitors, antimetabolite agents, and steroids, wildly used after transplantation, the new generation of immunosuppressive medicines have been developed, and cell-based immunotherapy, as mesenchymal stem cell, myeloid-derived suppressor cells, dendritic cells, pluripotent cells and Treg cells are promising to be used in cellular immunotherapy in organ transplantation.
Advancements in Cardiovascular Diagnostics
Fang, Karen L., Huang, Zhi , Lu, Yun , Yao, Yali, Li, Yan , Zhang, Bin

Mayo Clinic

Advances in Medical Diagnosis, Treatment, and Care | January 25, 2017 | Volume: No volume available | Issue: No issue available | Pages: 194-211

10.4018/978-1-5225-2092-4.ch011 Get It

The cardiology diagnostic are the methods of identifying current or past heart conditions, which can advise caregivers on patient diagnosis and provide a proper therapy plan, nowadays couple new diagnostic methods have been developed and some of them like radionuclide myocardial perfusion imaging, coronary computed tomography angiogram, cardiac magnetic resonance imaging, intravascular ultrasonography, optical coherence tomography, intravascular thermography, intravascular elastography, and near-infrared spectroscopy have been approved for clinical use. Not only the advanced technologies, the new biomarkers, and genetic markers may provide new potential targets for the diagnosis, therapy, and prevention of heart diseases.
A robust biomarker of large‐scale network failure in Alzheimer's disease
Wiepert, Daniela A. , Lowe, Val J. , Graff‐Radford, Jonathan, Petersen, Ronald C. , Jones, David T. , Knopman, David S. , Boeve, Bradley F. , Graff‐Radford, Jonathan , Jack, Clifford R. , Jones, David T

Mayo Clinic

Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring | January 25, 2017 | Volume: 6 | Issue: 1 | Pages: 152-161

10.1016/j.dadm.2017.01.004 | PMID 28275697 Get It

AbstractIntroductionBiomarkers for Alzheimer's disease (AD) pathophysiology have been developed that focus on various levels of brain organization. However, no robust biomarker of large‐scale network failure has been developed. Using the recently introduced cascading network failure model of AD, we developed the network failure quotient (NFQ) as a biomarker of this process.MethodsWe developed and optimized the NFQ using our recently published analyses of task‐free functional magnetic resonance imaging data in clinically normal (n = 43) and AD dementia participants (n = 28) from the Alzheimer's Disease Neuroimaging Initiative. The optimized NFQ (oNFQ) was then validated in a cohort spanning the AD spectrum from the Mayo Clinic (n = 218).ResultsThe oNFQ (d = 1.25, 95% confidence interval [1.25, 1.26]) had the highest effect size for differentiating persons with AD dementia from clinically normal participants. The oNFQ measure performed similarly well on the validation Mayo Clinic sample (d = 1.44, 95% confidence interval [1.43, 1.44]). The oNFQ was also associated with other available key biomarkers in the Mayo cohort.DiscussionThis study demonstrates a measure of functional connectivity, based on a cascading network failure model of AD, and was highly successful in identifying AD dementia. A robust biomarker of the large‐scale effects of AD pathophysiology will allow for richer descriptions of the disease process and its modifiers, but is not currently suitable for discriminating clinical diagnostic categories. The large‐scale network level may be one of the earliest manifestations of AD, making this an attractive target for continued biomarker development to be used in prevention trials.
A phase 2 study incorporating sorafenib into the chemotherapy for older adults with FLT3-mutated acute myeloid leukemia: CALGB 11001
Uy, Geoffrey L. , Mandrekar, Sumithra J. , Laumann, Kristina, Marcucci, Guido , Zhao, Weiqiang , Baer, Maria R. , Powell, Bayard L., Westervelt, Peter, DeAngelo, Daniel J. , Sanford, Ben L. , Blum, William , Bloomfield, Clara D. , Stone, Richard M. , Levis, Mark J. , Klepin, Heidi D. , Stock, Wendy , Larson, Richard A. , Uy, Geoffrey , Deangelo, D. J.

Mayo Clinic

Blood Advances | January 25, 2017 | Volume: 1 | Issue: 5 | Pages: 331-340

10.1182/bloodadvances.2016003053 | PMID 29034366 Get It

Key Points The addition of sorafenib to chemotherapy for older adults with FLT3-ITD mutated AML is safe and may improve overall survival.
Impact of Radical Prostatectomy on Long-Term Oncologic Outcomes in a Matched Cohort of Men with Pathological Node Positive Prostate Cancer Managed by Castration
Bhindi, Bimal , Rangel, Laureano J. , Mason, Ross , Gettman, Matthew T., Frank, Igor, Kwon, Eugene D., Tollefson, Matthew K. , Thompson, R. Houston, Boorjian, Stephen A. , Karnes, R. Jeffrey , Mason, Ross J

Mayo Clinic

Journal of Urology | January 25, 2017 | Volume: 198 | Issue: 1 | Pages: 86-91

10.1016/j.juro.2017.01.063 | PMID 28130104 Get It

Glial fibrillary acidic protein immunoglobulin G as biomarker of autoimmune astrocytopathy: Analysis of 102 patients
Flanagan, Eoin P. , Hinson, Shannon R., Lennon, Vanda A. , Fang, Boyan , Aksamit, Allen J. , Morris, Pearse , Basal, Eati, Honorat, Josephe A., Alfugham, Nora, Linnoila, Jenny, Weinshenker, Brian G. , Pittock, Sean J. , McKeon, Andrew , Morris, P Pearse, Alfugham, Nora B, Linnoila, Jenny J, Pittock, S J , Flanagan, E P , Weinshenker, Brian G , McKeon, Andrew

Mayo Clinic

Annals of Neurology | January 24, 2017 | Volume: 81 | Issue: 2 | Pages: 298-309

10.1002/ana.24881 | PMID 28120349 Get It

Objective A novel autoimmune central nervous system (CNS) disorder with glial fibrillary acidic protein (GFAP)‐IgG as biomarker was recently characterized. Here, 102 patients with GFAP‐IgG positivity are described. Methods The 102 included patients had: (1) serum, cerebrospinal fluid (CSF), or both that yielded a characteristic astrocytic pattern of mouse tissue immunostaining; (2) confirmation of IgG reactive with specific GFAP isoforms (α, ɛ, or κ) by cell‐based assays; and (3) clinical data available. Control specimens (n = 865) were evaluated by tissue (n = 542) and cell‐based (n = 323) assays. Results Median symptom onset age was 44 years (range = 8–103), and 54% were women. The predominant phenotype (83 patients; 81%) was inflammation of meninges, brain, spinal cord, or all 3 (meningoencephalomyelitis). Among patients, highest specificity for those phenotypes was observed for CSF testing (94%), and highest sensitivity was for the GFAPα isoform (100%). Rare GFAP‐IgG positivity was encountered in serum controls by tissue‐based assay (0.5%) or cell‐based assay (1.5%), and in CSF controls by cell‐based assay (0.9%). Among patients, striking perivascular radial enhancement was found on brain magnetic resonance imaging in 53%. Although cases frequently mimicked vasculitis, angiography was uniformly negative, and spinal imaging frequently demonstrated longitudinally extensive myelitic lesions. Diverse neoplasms encountered were found prospectively in 22%. Ovarian teratoma was most common and was predicted best when both N‐methyl‐D‐aspartate receptor–IgG and aquaporin‐4–IgG coexisted (71%). Six patients with prolonged follow‐up had brisk corticosteroid response, but required additional immunosuppression to overcome steroid dependency. Interpretation GFAPα‐IgG, when detected in CSF, is highly specific for an immunotherapy‐responsive autoimmune CNS disorder, sometimes with paraneoplastic cause. Ann Neurol 2017;81:298–309
Symptom Relief and Retreatment After Vaginal, Open, or Robotic Surgery for Apical Vaginal Prolapse
Anand, Mallika , Weaver, Amy L. , Fruth, Kristin M. , Trabuco, Emanuel C. , Gebhart, John B.

Mayo Clinic

Female Pelvic Medicine & Reconstructive Surgery | January 24, 2017 | Volume: 23 | Issue: 5 | Pages: 297-309

10.1097/spv.0000000000000389 | PMID 28118173 Get It

Objectives The aim of this work was to determine the degree of symptom relief and survival free of retreatment after Mayo-McCall culdoplasty (MMC), open abdominal sacrocolpopexy (ASC), and robotic sacrocolpopexy (RSC) for posthysterectomy vaginal vault prolapse. Methods We retrospectively studied patients who had undergone surgery for posthysterectomy apical vaginal prolapse from January 1, 2000, through June 30, 2012, at our institution. Baseline characteristics and perioperative outcomes were abstracted from electronic health records. Cross-sectional data for current pelvic floor symptoms were collected by using validated questionnaires. Survival free of retreatment was estimated with the Kaplan-Meier method. To account for selection bias, adjusted analyses using inverse probability weighting (IPW) were performed to compare outcomes for MMC versus ASC, MMC versus RSC, and ASC versus RSC. Results Of 512 patients, 337 completed at least a validated or abbreviated questionnaire. Among MMC, ASC, and RSC groups, overall Pelvic Floor Distress Inventory 20, Pelvic Floor Impact Questionnaire Short Form 7, and Pelvic Organ Prolapse/Urinary Incontinence Sexual Function Questionnaire 12 summary scores were not significantly different. There was no significant difference in 5-year survival free of retreatment for MMC (94.0%) versus RSC (95.5%) and ASC (94.8%) versus RSC (92.1%). However, patients who had MMC were more likely to have retreatment than patients who had ASC during the first 10 years (10-year survival free of retreatment: 81.1% vs 95.4%; hazard ratio, 3.68 [95% confidence interval, 1.51–8.98]); the 10-year data were not available for RSC comparisons, given the later initiation of RSC. Conclusions Symptom relief was comparable after MMC, ASC, and RSC. Among all groups, most patients were free of retreatment for prolapse at 5 years. Between the MMC and ASC groups, survival free of retreatment (%) within 10 years was still favorable, but ASC had greater durability, particularly after accounting for selection bias.
Trinucleotide Repeat Expansion in the Transcription Factor 4 ( TCF4 ) Gene Leads to Widespread mRNA Splicing Changes in Fuchs' Endothelial Corneal Dystrophy
Wieben, Eric D. , Aleff, Ross A., Tang, Xiaojia , Butz, Malinda L., Kalari, Krishna R. , Highsmith, Edward W., Jen, Jin , Vasmatzis, George , Patel, Sanjay V. , Maguire, Leo J., Baratz, Keith H. , Fautsch, Michael P. , Kalari, Krishna R , Patel, Sanjay V , Tang, Xiaojia

Mayo Clinic

Investigative Opthalmology & Visual Science | January 24, 2017 | Volume: 58 | Issue: 1 | Pages: 343

10.1167/iovs.16-20900 | PMID 28118661 Get It